Exabis Library
Welcome to the e-CCO Library!
P484: Access to biologics and biosimilars across 11 European Union countries
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P484: Dietary therapy using the Crohn's disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P484: Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P484: Hepatitis B vaccination in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P484: Inflammatory Bowel Disease exercise and diet habits (IBDeat) study: chronic metabolic disease risk factors among IBD patients in New Zealand
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P484: Infliximab and vedolizumab show a different effect on clot formation in inflammatory bowel disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P484: Remote monitoring allows an individualized approach and showed excellent usability at the infusion unit
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P485 Switching infliximab biosimilar: No adverse impact on inflammatory bowel disease control or drug levels with the first or second switch
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P485: An Assessment Of A Guided Self-Help and Patient Initiated Review Pathway for Ulcerative Proctitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P485: Apolipoprotein C3 is Downregulated in Patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P485: Development and implementation of a remote monitoring tool for real-world assessment of mild, moderate and severe infectious complications in Inflammatory Bowel Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P485: Dosing infliximab in Crohn's disease: Is adjustment for body size justified?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P485: Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P485: Real-world evidence (RWE) on outcomes and clinical treatment patterns of 5-aminosalicylic acid (5-ASA) in mild Crohn’s disease (CD) from European healthcare databases (the CROHN’S investigation)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P485: The combined of mesenchymal stem cells and infliximab reduces the recurrence rate of Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P486 Assessing the efficacy of biologics in ucerative colitis: a real-life, observational retrospective multicentre study with propensity score analysis (AURORA): Focus on patients naive to biologics
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P486: Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P486: Immunization status of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P486: Improving enhanced recovery after surgery (ERAS): the effect of a patient-centred mobile application on patient participation in colorectal surgery
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P486: Intrapatient variability in adalimumab drug levels within and across cycles in Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM